

Edgar Filing: GERON CORPORATION - Form 8-K

GERON CORPORATION
Form 8-K
March 10, 2004

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
SECURITIES AND EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 10, 2004

GERON CORPORATION

(Exact name of registrant as specified in its charter)

Delaware (State or Other Jurisdiction of Incorporation)	0-20859 (Commission File Number)	75-2287752 (IRS Employer Identification Number)
--	-------------------------------------	---

230 Constitution Drive Menlo Park, California (Address of principal executive offices)	94025 (Zip Code)
--	---------------------

(650) 473-7700
(Registrant's telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events.

On March 10, 2004, Geron Corporation, a Delaware corporation (the "Company") and Merix Bioscience, Inc., a Delaware corporation ("Merix") announced that the companies have executed an agreement (the "Agreement") under which the Company has acquired a license under Merix's platform technology, including the exclusive right to use the platform technology in therapeutic cancer vaccines using the enzyme telomerase as an antigen.

The Company's press release announcing the Agreement is filed as an exhibit to this Current Report on Form 8-K. The summary description of the transaction and the press release are qualified in their entirety by reference to the document filed as an exhibit hereto.

Item 7. Exhibits.

Exhibits

99.1 Press Release dated March 10, 2004

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GERON CORPORATION

Date: March 10, 2004

By: /s/ William D. Stempel

Name: William D. Stempel

Title: Vice President and General Counsel

EXHIBIT INDEX

Exhibits

99.1

Press Release dated March 10, 2004